RIGI and hepatocellular carcinoma: NFATc3 binds to the promoter regions of IFNL1 and IFNB1 to activate their transcription in a synergistic manner with the RIG-I pathway, which can inhibit hepatitis B virus replication and hepatocellular carcinoma tumorigenesis.